APLI — Appili Therapeutics Cashflow Statement
0.000.00%
- CA$3.64m
- CA$14.74m
- CA$0.83m
Annual cashflow statement for Appili Therapeutics, fiscal year end - March 31st, CAD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -5.42 | -14.3 | -25.1 | -9.24 | -3.78 |
Depreciation | |||||
Non-Cash Items | 0.694 | 1.22 | 3.54 | 2.37 | 0.641 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.444 | 1.64 | 2.49 | -3.24 | 0.661 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -4.26 | -11.5 | -19.1 | -10.1 | -2.46 |
Capital Expenditures | -0.001 | -0.008 | 0 | -0.003 | -0.03 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -0 | -4.98 | 5.06 | 0 | 0.001 |
Sale of Fixed Assets | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.001 | -4.99 | 5.06 | -0.003 | -0.029 |
Financing Cash Flow Items | -1.12 | -1.42 | -1.31 | -1.01 | -0.082 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 9.36 | 17 | 9.56 | 5.91 | 0.122 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 5.09 | 0.553 | -4.4 | -4.2 | -2.37 |